suMmARY The administration of vasodilator drugs has been shown to have beneficial effects at rest in patients with acute or chronic heart failure. To determine the efficacy of hydralazine during exercise, 10 severely symptomatic patients with chronic left ventricular failure from diffuse coronary disease or cardiomyopathy were studied at rest and during upright exercise on a bicycle ergometer. All patients were already receiving optimal treatment with digitalis and diuretics.
The improvement in survival of patients admitted to coronary care units with acute myocardial infarction and the reduction in post-infarct mortality with the use of antiarrhythmic treatment has resulted in an increasing number of patients who manifest symptoms and signs of poor ventricular function and in whom the use of conventional antifailure treatment with digitalis and diuretics has failed to result in significant improvement. In these patients and in patients with ventricular failure resulting from other forms of cardiomyopathy, the administration of vasodilator drugs has been shown to result in beneficial haemodynamic changes.'-"
Thus sodium nitroprusside given intravenously lowers systemic vascular resistance and reduces impedance to ventricular ejection. Consequently cardiac output increases with only small changes in the arterial pressure. At the same time, because of more effective ventricular emptying and because of an increase in venous capacitance consequent upon the venodilatory effects of nitroprusside, ventricular filling pressures are reduced. Thus the two major effects of chronic pump failure are alleviatedReceived for publication 15 October 1979 namely impaired organ perfusion and raised pulmonary venous pressure. While these beneficial effects follow the acute administration of intravenous sodium nitroprusside, its use in the longterm management of heart failure is clearly not feasible. Further studies have therefore examined the effects of other vasodilator drugs which can be administered orally. Nitrates qualitatively mimic the effects of treatment with nitroprusside by causing a significant reduction in left ventricular filling pressure7 8 but a less impressive change in cardiac output.9 10 Treatment with hydralazine, an arterial dilator, increases the cardiac output as much as nitroprusside but seems to be less effective in reducing left ventricular filling pressure."1- '6 These studies have analysed the acute effects of drugs used at rest and little attention has been paid to their effects during upright exercise where the major benefit of such treatment would be sought.
The present study has therefore been undertaken to assess the haemodynamic effects of orally admininistered hydralazine, at rest and during upright bicycle exercise, in patients with chronic left ventricular failure from myocardial disease. 100  47  28  100  1-50  40  15  98  55   2  CD  89  35  27  80  1-252  29  17  85  35  3  CD  105  16  5  84  1-49  31  14  107  12  4  CD  100  25  16  80  2-053  24  20  100  25  5  CD  90  29  22  80  2-053  24  23  100  32  6  CD  90  13  8  92  2-455  24  27 exercise, before and three hours after the oral administration of hydralazine. Under resting conditions hydralazine produced a significant fall in mean pulmonary venous pressure from an average of 18 ±3 0 to 14 ±3-5 mmHg (p < 0 05); at peak exercise, a significant reduction in mean wedge pressure also occurred after treatment, from 30 ±1 6 to 23 + 1 1 mmHg (p < 0 01) (Fig. 1) . Similar haemodynamic effects on mean arterial pressure were observed. Thus mean arterial pressure fell from 87 ±2-1 to 70 ±3-6 mmHg (p <0-01) after treatment at rest and from 86 ±5-0 to 76 ±39 mmHg (p <0-01) during peak exercise (Fig. 2) . The fall in arterial pressure was related to a striking reduction in arterial resistance. At rest, arterial resistance fell from an average of 27 ±1-9 35- the sternal angle. Baseline haemodynamic measurements were obtained with the patient sitting upright at rest on the bicycle ergometer. The patient then performed graded exercise to the point of maximal exercise tolerance when haemodynamic recordings were repeated before the termination of exercise with dyspnoea or fatigue. After this control studSy the patients rested supine and were given 50 to 75 mg hydralazine orally (a dose of 1 mg/kg body weight was given based on earlier haemodynamic observations). Cardiac output determinations and pressure measurements were repeated at rest and during maximum exertion three hours later. Tables 1 and 2 show the haemodynamic variables in the 10 patients both at rest and during maximal 29 ±2'8 to 36 ±3-4 ml/m2 after treatment (p < 0 01).
Results
In one patient stroke volume actually fell during exertion after hydralazine (41 to 38 ml/m2) and this was probably related to an excessive reduction in filling pressure induced by the drug in this patient.
The haeiiodynamic changes occurring after treatment with hydralazine may be expressed as the average percentage change compared with pretreatment measurements. At rest, there was a significant reduction in both arterial and pulmonary wedge pressure. There was a 50 per cent reduction in systemic vascular resistance and an equally striking increase in stroke volume index. During exertion the shifts seen in the resting state were maintained but occurred to a considerably lesser degree; thus there was a 20 per cent fall in systemic vascular resistance and a 20 per cent rise in stroke volume index compared with control. In order to analyse the effects of hydralazine on left ventricular performance, points on the function curve were plotted in the conventional manner by comparing the average pulmonary wedge pressure with the average stroke volume index, both at rest and at peak exercise (Fig. 5) . At rest, stroke volume index increased from 21 to 33 ml/m2 after hydralazine while there was a coincident slight but significant reduction in filling pressure (from 18 to 14 mmHg). During exercise treatment with hydralazine resulted in a similar directional change in stroke volume (from 29 to 36 ml/m2, p < 001). Thus there appeared to be an overall shift of the function curve upwards and to the left suggesting improved left ventricular function.
Discussion
Systemic vascular resistance is increased in the setting of chronic left ventricular failure since arterial pressure is often normal or sometimes raised in the face of a pronounced reduction in cardiac output. 17 Multiple factors may be respon- The reduction in left ventricular filling pressure after treatment with hydralazine is a probable consequence of more effective left ventricular emptying resulting from decreased impedance to ejection. This reduction in diastolic pressure and volume will result in an improved oxygen demand: supply ratio which will prevent or delay myocardial ischaemia during stress in patients with ischaemic cardiomyopathy and thus help to preserve myocardial function.
During peak exercise the magnitude of change in cardiac output after treatment with hydralazine is less obvious for the group overall than that observed under resting conditions. This is an expected finding, since it would be very unlikely, that under conditions of stress, impaired pump function would be able to improve as much as at rest however potent the stimulus. In addition, quite distinct variations between patients in the increment in cardiac output duwng exercise after hydralazine were observed i6$ this probably related to the aetiology of the heart failure, its severity, and duration. Exercisq tolerance in all patients, when assessed after the acute administration of hydralazine, was not improved even in those subjects where a considerable increase in cardiac output had been measured during maximal exertion. It is possible, therefore, that hydralazine results in an increase in cardiac output which is preferentially distributed to cutaneous, hepatic, splanchnic, and renal vascular compartments."l 20 In conclusion this study confirms the beneficial effect of hydralazine on resting cardiac function in patients with chronic heart failure. This improvement in cardiac function is sustained, though to a lesser extent, during upright exercise. Though these results provide further support for the use of vasodilators in the long-term management of patients with chronic heart failure, questions arise concerning the wide individual patient variation in response to treatment. Furthermore, though cardiac output is increased by hydralazine, more information about the regional vascular effects of such agents is required. 
